MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that
the Québec government has approved the inclusion of Victoza® (liraglutide), the first once-daily human glucagon-like peptide-1
(GLP-1) analogue, to the Lists of Medications, effective June 2, 2014.
The reimbursement of Victoza® by the Québec Health Insurance Board (RAMQ) will allow people living
with type 2 diabetes to have access to a treatment to help better
manage diabetes. Québec is the first province to provide public access
Effective June 2, 2014, Victoza® is covered for eligible people in Québec, in association with
metformin, for the treatment of type 2 diabetes for those whose
glycemic control is inadequate and whose body mass index (BMI) is
greater than 30 kg/m2 when a dipeptidyl peptidase 4 (DPP-4) inhibitor is contraindicated, not
tolerated or ineffective. Authorization for an initial request for
treatment with Victoza® is granted for a maximum of 12 months. When submitting the first
request for continuation of treatment, the physician must provide proof
of a beneficial effect defined by a reduction in the glycated
hemoglobin (HbA1c) of at least 0.5 per cent or by the attainment of a
target value of seven per cent or less.
According to the 2013 Clinical Practice Guidelines from the Canadian
Diabetes Association, proper management of type 2 diabetes includes
reaching target HbA1c levels within three to six months of initial
treatment, reduction in rates of hypoglycemia and weight loss. If these
goals are not achieved in the first three to six months, the guidelines
suggest incorporating timely adjustments, such as including an
Victoza® is an anti-hyperglycemic agent which improves glycemic control by
lowering blood glucose and HbA1C levels, with a low risk of
hypoglycemia and the added benefit of weight loss.2,3
Perspectives from Key Authorities on Diabetes in Québec:
"An important point for type 2 diabetes management is to ensure that
most patients are reaching their HbA1c goals," said Dr. Rémi
Rabasa-Lhoret, MD, PhD, associate professor, Université de Montréal.
"If this is not achieved through diet and exercise and the recommended
first-line therapy, metformin, an anti-hyperglycemic treatment like
Victoza® should be initiated. The Québec government's reimbursement of Victoza® should provide some patients with access to a treatment to better
manage their diabetes."
"Victoza® is a leading therapeutic option for an individualized approach to
treating type 2 diabetes and preventing hypoglycemia, as numerous
studies have confirmed its efficacy in achieving glycemic goals while
having a very low risk of hypoglycemia," said said Dr. Sylvie Bertrand,
MD, CSPQ FRCS. "Unlike other treatments traditionally used in type 2
diabetes, Victoza® does not cause weight gain and has even promoted weight loss in many
patients. The Québec government's decision to cover Victoza® as a treatment of exception will provide these benefits to a larger
number of people who live with type 2 diabetes."
"To ensure blood glucose and HbA1c levels are in the target ranges, it
is important to work with type 2 diabetes patients to adjust and refine
treatments as required," said Dr. André Bélanger, MD, CFPC. "The
listing of Victoza® now presents opportunities for GPs to help their patients reach their
targets through an effective non-insulin injectable therapy. Treatment
with Victoza® allows us to more often reach a composite objective by lowering the
blood sugar levels without inducing hypoglycemia, while promoting
weight loss for the patient."
"Promoting the cause of people with diabetes has always been a priority
of our organization," said Serge Langlois, President and CEO of Diabète
Québec. "The introduction of new drugs that improve treatment is always
a source of hope to help reduce complications associated with
diabetes. We applaud the favourable decision of the Prescription Drug
Victoza® is the first once-daily, injectable, GLP-1 for the treatment of adults
with type 2 diabetes to improve glycemic control in combination with
metformin, when diet and exercise plus maximal tolerated dose of
metformin do not achieve adequate glycemic control; metformin and a
sulfonylurea, when diet and exercise plus dual therapy with metformin
and a sulfonylurea do not achieve adequate glycemic control; or
metformin and a basal insulin, when diet and exercise plus dual therapy
with Victoza® and metformin do not achieve adequate glycemic control.4
Victoza® is the leading GLP-1 treatment worldwide for type 2 diabetes, and
currently there are more than 800,000 Victoza® patients worldwide.5 Victoza® has a 24-hour duration of action and improves glycemic control by
lowering fasting and postprandial blood glucose in patients with type 2
diabetes.4 Victoza® should not be used in patients with type 1 diabetes.4 The safety and efficacy of Victoza® has been extensively investigated in studies involving more than 6,000
people6 and is currently prescribed in over 69 countries worldwide.
Victoza® is administered once daily at any time, independent of meals, by a
pre-filled pen injection device in the abdomen, thigh or upper arm. It
is not necessary to adjust the dose based on weight. Dosing starts at
0.6 mg and increases to 1.2 mg after one week up to 1.8 mg if needed.4
For information about Victoza®, including important safety information, please visit http://novonordisk.ca/PDF_Files/our_products/Victoza/Victoza_PM_EN.pdf.
About Diabetes in Canada and Québec:
Diabetes is a life-long, often debilitating and sometimes fatal disease
in which the body either cannot produce insulin or cannot properly use
the insulin it produces. This leads to high levels of glucose in the
blood, which can damage organs, blood vessels and nerves.7 Type 2 diabetes occurs when the pancreas does not produce enough
insulin to meet the body's needs, or the body is unable to respond
properly to the actions of insulin.7
Approximately 760,000 people are living with diabetes in Québec.8 In Canada, approximately three million people are living with diabetes.9 Ten per cent of these live with type 1 diabetes, and 90 per cent live
with type 2.9 Forty-nine per cent of Canadians living with type 2 diabetes have a BMI
of 30 kg/m2 or greater.10
The cost of diabetes to Canada's healthcare system and economy was $11.7
billion in 2010, which is projected to increase to $16 billion annually
About Novo Nordisk Canada Inc.
Novo Nordisk is a healthcare company and a world leader in diabetes care
and biopharmaceuticals. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant difference
to patients, the medical profession and society. Novo Nordisk's
business is driven by the Triple Bottom Line: a commitment to economic
success, environmental soundness, and social responsibility to
employees and customers. For more information, visit www.novonordisk.ca.
* Under special authorization, 'Medicament d'Exception'
1 Clinical Practice Guidelines. Canadian Diabetes Association, 2013, pg.
2 Zinman B. et al. Achieving a clinically relevant composite outcome of
an HbA1c of <7% without weight gain or hypoglycemia in type 2 diabetes: a
meta-analysis of the liraglutide clinical trial programme. Diabetes, Obesity and Metabolism, 2011.
3 Pratley R. E. et al. Efficacy and Safety of Switching From the DPP-4
Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52
Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care
4 Victoza® Product Monograph, Novo Nordisk, March 14, 2014.
5 Internal Calculations based on IMS Midas Quantum data, May 2012 (Data
6 Data on file Novo Nordisk A/S 2012.
7 "What is Diabetes", Canadian Diabetes Association. Accessed May 27,
2014. Available at http://www.diabetes.ca/about-diabetes/what-is-diabetes.
8 "What is Diabetes", Diabetes Québec. Accessed May 27, 2014. Available
9 "Diabetes", Canadian Diabetes Association. Accessed May 27, 2014.
Available at http://guidelines.diabetes.ca/CDACPG/media/documents/patient-resources/diabetes.pdf.
10 GfK 2012 Roper Canadian Diabetes Patient Study, slide 27.
11 "Diabetes: Canada at the Tipping Point", Diabetes Québec and Canadian
Diabetes Association, pg. 2. Accessed May 27, 2014. Available at: http://www.diabete.qc.ca/pdf/rapport/WEB_Eng_CDA_Report.pdf.
SOURCE: Novo Nordisk Canada Inc.
For further information:
For more information, or to arrange an interview with a spokesperson, please contact:
Novo Nordisk Canada Inc.
418-529-3223 poste 34